The cash flow of Cellebrite DI Ltd. over the past 7 years
Chart Cellebrite DI Ltd.: operating cash flow, capital expenditures, free cash flow, fiscal 2019–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Cellebrite DI Ltd.'s operating cash flow was $173.54M and its capital expenditures $13.22M, leaving free cash flow of $160.32M. Free cash flow was above zero in all 7 years shown. It ranged from $9.92M in fiscal 2019 to $160.32M in fiscal 2025. Capital expenditures were highest in fiscal 2025, at $13.22M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $173.54M | $13.22M | $160.32M |
| 2024ended Dec 31, 2024 | $132.17M | $8.57M | $123.61M |
| 2023ended Dec 31, 2023 | $102.06M | $5.23M | $96.83M |
| 2022ended Dec 31, 2022 | $20.58M | $6.9M | $13.68M |
| 2021ended Dec 31, 2021 | $36.05M | $5.11M | $30.94M |
| 2020ended Dec 31, 2020 | $66.51M | $6.18M | $60.33M |
| 2019ended Dec 31, 2019 | $16.13M | $6.21M | $9.92M |
Fiscal years as Cellebrite DI Ltd. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Cellebrite DI Ltd.
- The revenue of Cellebrite DI Ltd.
- The profitability of Cellebrite DI Ltd.
- The debt of Cellebrite DI Ltd.
- All of Cellebrite DI Ltd.'s financials, charted
Companies of a similar size
- KNFKnife River Corporation
- AMLXAmylyx Pharmaceuticals, Inc.
- EEFTEURONET WORLDWIDE, INC.
- IMAXIMAX Corporation
- PFSPROVIDENT FINANCIAL SERVICES INC
Not investment advice. This page shows what Cellebrite DI Ltd. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.